PMID- 8873586
OWN - NLM
STAT- MEDLINE
DCOM- 19961108
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 47
IP  - 10
DP  - 1996 Oct
TI  - Postphlebitic syndrome: clinical activity and tolerability of desmin, new LMW 
      dermatan sulfate.
PG  - 1001-10
AB  - One hundred patients suffering from postphlebitic syndrome of the lower limbs 
      were enrolled in an open, randomized, and multicenter (six centers) trial for a 
      period of eighteen months. Patients were randomly assigned to three treatment 
      groups to receive (for ninety consecutive days) Desmin, a new 
      low-molecular-weight dermatan sulfate, at the dose, respectively, of 100 mg once 
      daily by subcutaneous (SC) route (36 patients), 100 mg twice a day by SC route 
      (33 patients), and 200 mg once daily by intramuscular (IM) route (31 patients). 
      The general and local tolerability and the clinical efficacy of the drug were 
      evaluated by means of clinical, instrumental, and laboratory parameters. Desmin 
      is effective in the decompensation stage of postphlebitic syndrome; this was 
      demonstrated by a significant reduction in the severity of a number of typical 
      symptoms as well as by the drug's positive effect on venous tone as confirmed by 
      phlebotensiometric examination. The daily dose of 200 mg (either SC or IM) was 
      more effective than the 100 mg dose. The results obtained at the end of the trial 
      (ninety days) were statistically better than those obtained after thirty days of 
      treatment. This trial demonstrated that both the systemic and the local (at the 
      site of injection) tolerability of the drug, administered for three months, were 
      good and without significant variations in the laboratory parameters monitored.
FAU - Andreozzi, G M
AU  - Andreozzi GM
AD  - Department of Internal Medicine, University of Catania, Rome, Italy.
FAU - Signorelli, S
AU  - Signorelli S
FAU - Di Pino, L
AU  - Di Pino L
FAU - Allegra, C
AU  - Allegra C
FAU - Riccioni, C
AU  - Riccioni C
FAU - Cucinotta, D
AU  - Cucinotta D
FAU - Manopulo, R
AU  - Manopulo R
FAU - Dettori, A G
AU  - Dettori AG
FAU - Megha, A
AU  - Megha A
FAU - Longo, F N
AU  - Longo FN
FAU - Urbano, O
AU  - Urbano O
FAU - Manganaro, A
AU  - Manganaro A
FAU - Buda, D
AU  - Buda D
FAU - Zamboni, V
AU  - Zamboni V
FAU - Palazzini, E
AU  - Palazzini E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Desmin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Desmin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Leg/blood supply
MH  - Male
MH  - Middle Aged
MH  - Postphlebitic Syndrome/*drug therapy
MH  - Ultrasonography
MH  - Veins/diagnostic imaging
MH  - Venous Pressure/drug effects
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1177/000331979604701009 [doi]
PST - ppublish
SO  - Angiology. 1996 Oct;47(10):1001-10. doi: 10.1177/000331979604701009.